1Gandhi V, Estey E, keating M J, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol,1993,11:116-124.
2Bai A,Kojima H,Hori M,et al. Priming with G-CSF effectively enhance low-dose Ara-c induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol, 1999,27 : 259 -265.
3Hubeek I, Litvinova E, Peters G J, et al. The effect of G-CSF on the in vitro cytutoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. Int J Oncol,2004,25:1823-1829.
4Higashi Y, Turzanski J, Pallis M, et al. Contrasting in vitro effects for the combination of fludarabine, cytosine (Ara-c) and granulocyte colonystimulating factor (FLAG) compared with daunorubicin and Ara-c in Pglycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukemia. Br J Haematol,2000,111:565-569.
6Moricke A, Reiter A,Zimmermann M,et al. Risk -adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL - BFM 95 [ J ]. Blood, 2008,111 ( 9 ) : 4477 - 4499.
7Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia[ J]. Semin Hematol,2009,46( 1 ) :52 - 63.
8Bashey A, Liu L, Ihasz A, et al. Non - anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older[J]. Leuk Res,2006,30(4) :503 -506.
9McCarthy AJ, Pitcher LA, Harm IM, et al. FLAG ( fludarabine, high - dose cytarabine ,and G- CSF)for refractory and high -risk relapsed acute leukemia in children [ J ]. Med Pediatr Oncol, 1999,32 (6) :411 - 415.
